MOLOGEN AG. Our research for you. German Equity Forum November 2012

Size: px
Start display at page:

Download "MOLOGEN AG. Our research for you. German Equity Forum November 2012"

Transcription

1 Our research for you. German Equity Forum November 2012

2 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication. V

3 Agenda at a glance Product pipeline Overview MGN cancer immuno-therapy MGN1601 therapeutic vaccination against cancer Milestones 2012 / 2013 Financial overview / MOLOGEN share

4 At a glance: cancer immuno-therapies with blockbuster market potential DNA cancer drug MGN1703 ready to enter phase III in colorectal cancer - applicable in other malign solid tumors also (e.g. lung cancer ) - blockbuster market potential Cell-based cancer therapy MGN1601 in phase I/II in renal cancer - Made from proprietary allogeneic renal cancer cell line DNA vaccines against leishmaniasis and hepatitis B in preclinical development Strong capital resources IPO in 1998, listed on Frankfurt Stock Exchange: Prime Standard (MGN) 51 employees, based in Berlin

5 Major achievements 2012 Outstanding data from two clinical trials for MGN1703 (phase II in colorectal cancer) and MGN1601 (phase I/II in renal cancer) Application for phase II trial with MGN1703 in lung cancer Successful capital increases 25 million Collaboration with Max Delbrück Centrum and Charité in clinical study on skin cancer

6 Advanced product pipeline with lead product against colorectal cancer Product Research Pre-clinic Phase I Phase II Phase III Approval Oncology MGN1703-CRC colorectal cancer Pivotal study being prepared MGN1703-NSCLC non-small cell lung cancer Phase II study submitted MGN1703 other solid tumors MGN1601-RCC renal cell carcinoma Phase II study being prepared Infectious Diseases MGN1331 leishmaniasis Phase I study being prepared MGN1333 hepatitis B * The mechanism of action of the products are based on the findings of the three winners of the 2011 Nobel Prize for Medicine

7 cancer immuno-therapy MGN

8 MGN1703 dslim Our Best in Class TLR9 agonist MGN1703 is the project name for the dslim DNA molecule no open ends - protection against degradation contains only natural DNA components no chemical modifications high stability proof of efficacy in phase II only minimal side effects no dose-limiting toxicity high dosing over long periods of time broad activation of the immune system

9 MGN1703 The impact of dslim on the immune system

10 MGN1703 Excellent safety and tolerability Both clinical trials confirm Very good tolerability No added Quality-of-Life burden for patients No serious adverse events No drug-associated withdrawals at any dose Mild and transient fever as typical signs of an immune response Long-term treatment with MGN1703 is safe and very well tolerated

11 MGN1703 Active principle proven Strong activation of important immune cells and cytokines Level of expression compared to pre-treatment (100%, red line) CD40 of PDC CD69 of NK cells CD69 of NKT cells CD69 of T-cells CD86 of MDC CD86 of monocytes IP-10 0% 100% 200% 300% 400% 500% 600% PDC: plasmacytoidal dendritic cells NK cells: natural killer cells MDC: myeloid dendritic cells NKT cells: natural killer T-cells

12 MGN1703 IMPACT colorectal cancer trial Study design (1/2) Phase II study to evaluate efficacy and safety of a maintenance therapy with MGN1703 after standard first-line therapy in patients with metastatic colorectal cancer disease control? if so: stop first-line therapy tumor progression? if so: stop maintenance therapy, start second line therapy First-line therapy duration: c months Maintenance therapy MGN1703 or placebo Second-line therapy evaluation of progression-free survival (period in which a cancer disease does not get worse)

13 MGN1703 IMPACT colorectal cancer trial Study design (2/2) Clinical trial phase II placebo-controlled double-blind randomized (2:1) multi-center phase III study design Subcutaneous injection, twice-weekly treatment until tumor progression Commenced June 2010 Recruitment terminated prematurely in May 2012 ClinicalTrials.gov Identifier NCT

14 MGN1703 Excellent outcome for IMPACT trial Primary analysis on 55 patients Population MGN1703 Placebo All Intent-to-treat (ITT) Good risk sub-group* *Exclusion of bad risk and not eligible pts (i.e. secondary tumor, second-line therapy, etc.) Proof of efficacy provided: Progression of cancer disease delayed Risk for tumor progression reduced drastically ( hazard ratio ) Results of subgroup are statistically significant High reliability of the data due to placebo-controlled study design

15 MGN1703 Progression free survival (PFS) Intent-to-treat population PFS rate Patients Events Risk group MGN Placebo Log-rank test: p-value HR = 0.53 [95% CI: 0.27; 1.06] Months [95% CI] PFS MGN1703 Placebo Median PFS 25% quartile 75% quartile 2.8 [2.8; 6.6] 2.1 [1.6; 2.8] 7.4 [2.9;15.6] 2.6 [2.5; 2.8] 2.2 [1.7; 2.6] 2.8 [2.6; 2.9] Number at risk Months MGN Placebo Abbreviations: HR, Hazard ratio; CI, Confidence interval

16 MGN1703 Progression free survival (PFS) Good risk subgroup PFS rate Patients Events Risk group MGN Placebo Log-rank test: p-value HR = 0.39 [95% CI: 0.18; 0.85] Months [95% CI] PFS MGN1703 Placebo Median PFS 25% quartile 75% quartile 5.8 [2.8; 12.5] 2.8 [1.8; 4.1] 12.5 [5.8;15.6] 2.7 [2.5; 2.8] 2.5 [2.2; 2.8] 2.8 [2.6; 2.9] Number at risk Months MGN Placebo Abbreviations: HR, Hazard ratio; CI, Confidence interval

17 MGN1703 Next steps Intensify license talks with potential partners Close license deal with pharma company Prepare pivotal trial: Consult with KOL to agree on study design Consult with FDA and EMA and clear study design (e.g. patient numbers, clinical endpoints) Apply for clinical trial in EU and USA Manufacture of IMP

18 MGN1703 High revenue potential of MGN1703 Global cancer market 2009: c. $50bn (+6%), forecast: CAGR >7% between CRC incidence EU/USA: c. 380,000; CRC prevalence EU/USA: c. 1.2 million; comparable numbers for NSCLC Peak sales expectations for MGN1703 in CRC and NSCLC: 1-2 billion each Peak sales total > 3-4bn for success in all solid tumor types Deal expectations: significant upfront and milestone payments, royalties

19 therapeutic vaccination against cancer MGN

20 MGN1601 Therapeutic vaccination against cancer The mechanism of action of MGN

21 MGN1601 ASET renal cancer trial Study design Clinical trial phase I/II (safety study), initially 24 patients planned Open-label, multi-center Intradermal injection Commenced in December 2010 Excellent tolerability: early completion of recruitment in November 2011 after inclusion of 19 patients Inclusion criteria Disease Control? Extension phase Endpoints Patients with advanced renal cell cancer Treatment phase 8 applications in 12 weeks Max 5 applications in week 24, 36, 48, 72, and 120 Safety Pharmacodynamics Immunological data Radiological and clinical response

22 MGN1601 ASET renal cancer trial Excellent survival data Very good safety and tolerability Only mild and moderate adverse events, e.g. fever Very promising efficacy data on overall survival TPP group Patients received 8 injections 7 of 10 alive Median overall survival > 16 months non-tpp group Patients dropped out prematurely 0 of 9 alive Median overall survival < 3 months

23 MGN1601 Next steps Scientific advice with Paul-Ehrlich-Institut conducted Planning and preparation of phase II trial Apply for clinical trial Strategy: Development of MGN1601 until market approval Commercialization together with distribution partners Full exploitation of revenue potential

24 KEY FINANCIALS AND SHARE INFORMATION

25 Key financials as at September 30, 2012 (IFRS) R&D activities intensified Solid funding: gross proceeds from capital increases totaling 25 million Average monthly cash utilization: 0.6 million (nine months 2011: 0.5 million) R&D expenses EBIT months months 2012 Funds Balance Sheet Total [ m]

26 MOLOGEN share ISIN DE Number of shares: 15,396,990 Market cap : c. 199m Daily trading volume: c. 15,000 shares (average) Indices : DAXsector Pharma & Healthcare Index, DAXsubsector Biotechnology, CDAX Analysts coverage: buy recommendations current price targets Distribution of shares 1-year performance Deutscher Ring Sachversicherungs-AG Baden-Wuerttembergische Versorgungsanstalt für Aerzte BUCHRI GmbH, incl. shares from Prof. Wittig (founder) Deutscher Ring Lebensversicherungs-AG Salvator Vermoegensverwaltungs GmbH Deutscher Ring Krankenversicherungsverein a.g. Global Derivative Trading GmbH 40% 3% 3% 4% 6% 8% 9% DAXsector Pharma & Healthcare DAXsubsector Biotechnology 180% 160% 140% 120% 100% Freefloat 27% 80% 11/01/ /31/

27 Milestones 2012/2013 MGN1703 Apply for phase II study in lung cancer Interim analysis colorectal cancer study: May 2012 Presentation of detailed data at ESMO 2012 Start of phase II study in lung cancer License deal with pharma partner Start of pivotal trial in colorectal cancer MGN1601 Scientific Advice with competent authority in Q Start of phase II trial in renal cancer DNA vaccines Finalize preclinical work and prepare phase I studies

28 MOLOGEN Well prepared for the future Technology leader in the field of DNA-based and cell-based therapies Best-in-class immuno modulator dslim Proof-of-efficacy for lead candidate provided Promising and maturing product pipeline Products with outstanding market potential Broad patent protection of proprietary platform technologies Strong capital resources Highly qualified, motivated and dedicated team

29 Contact Fabeckstraße 30 D Berlin Germany Phone: Fax: V MOLOGEN, MIDGE and dslim are registered trademarks of the 28

MOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013

MOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013 Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,

More information

Our research for you. German Equity Forum November 2011

Our research for you. German Equity Forum November 2011 Our research for you. German Equity Forum 21-23 November 2011 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as

More information

MOLOGEN AG Jefferies 2014 London Healthcare Conference

MOLOGEN AG Jefferies 2014 London Healthcare Conference Jefferies 2014 London Healthcare Conference Dr. Matthias Schroff Chief Executive Officer London 20 November 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring

More information

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014 Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,

More information

9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO

9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO 9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,

More information

MOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO

MOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to

More information

MOLOGEN AG. Company Presentation October 2015

MOLOGEN AG. Company Presentation October 2015 Company Presentation October 2015 Agenda Business Overview Market MGN1703 Cancer Immunotherapy MGN1601 Therapeutic Vaccination against Cancer EnanDIM New Generation of Immunomodulators Key Financials and

More information

RODMAN & RENSHAW 18 TH ANNUAL GLOBAL INVESTMENT CONFERENCE DR. MARIOLA SÖHNGEN - CEO NEW YORK, 13 SEPTEMBER

RODMAN & RENSHAW 18 TH ANNUAL GLOBAL INVESTMENT CONFERENCE DR. MARIOLA SÖHNGEN - CEO NEW YORK, 13 SEPTEMBER RODMAN & RENSHAW 18 TH ANNUAL GLOBAL INVESTMENT CONFERENCE DR. MARIOLA SÖHNGEN - CEO NEW YORK, 13 SEPTEMBER 2016 www.mologen.com Disclaimer Certain statements in this presentation contain formulations

More information

GERMAN EQUITY FORUM 2017

GERMAN EQUITY FORUM 2017 GERMAN EQUITY FORUM 2017 DR. MARIOLA SÖHNGEN- CHIEF EXECUTIVE OFFICER FRANKFURT, 28 NOVEMBER 2017 www.mologen.com Disclaimer This presentation does not constitute an offer to buy shares or other securities

More information

MOLOGEN AG. Company Presentation February 2016

MOLOGEN AG. Company Presentation February 2016 Company Presentation February 2016 Agenda Business Overview Market Lefitolimod (MGN1703) Cancer Immunotherapy MGN1601 Therapeutic Vaccination against Cancer EnanDIM New Generation of Immunomodulators Key

More information

MOLOGEN AG. Company Presentation April 2016

MOLOGEN AG. Company Presentation April 2016 Company Presentation April 2016 Agenda Business Overview Market Lefitolimod (MGN1703) MGN1601 Therapeutic Vaccination against Cancer EnanDIM New Generation of Immunomodulators Key Financials and Outlook

More information

H RESULTS DR IGNACIO FAUS CEO WALTER MILLER CFO BERLIN, 9 AUGUST 2018

H RESULTS DR IGNACIO FAUS CEO WALTER MILLER CFO BERLIN, 9 AUGUST 2018 H1 2018 RESULTS DR IGNACIO FAUS CEO WALTER MILLER CFO BERLIN, 9 AUGUST 2018 1 DISCLAIMER This presentation does not constitute an offer to buy shares or other securities of MOLOGEN AG and does not replace

More information

BERENBERG AND GOLDMAN SACHS 7 TH GERMAN CORPORATE CONFERENCE

BERENBERG AND GOLDMAN SACHS 7 TH GERMAN CORPORATE CONFERENCE BERENBERG AND GOLDMAN SACHS 7 TH GERMAN CORPORATE CONFERENCE DR IGNACIO FAUS MUNICH, 25 SEPTEMBER 2018 1 DISCLAIMER This presentation does not constitute an offer to buy shares or other securities of MOLOGEN

More information

Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell

Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell carcinoma patients June 2013 Carbonic Anhydrase IX (CAIX):

More information

Dynavax Corporate Presentation

Dynavax Corporate Presentation Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,

More information

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated

More information

Nektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018

Nektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018 Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the

More information

Corporate Presentation October 2018 Nasdaq: ADXS

Corporate Presentation October 2018 Nasdaq: ADXS Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements

More information

COMPANY PRESENTATION MAY/JUNE

COMPANY PRESENTATION MAY/JUNE COMPANY PRESENTATION MAY/JUNE 2017 www.mologen.com Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments, as well as negations

More information

July, ArQule, Inc.

July, ArQule, Inc. July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical

More information

Company update. March 2012

Company update. March 2012 Company update March 2012 Oncology-focused biopharmaceutical company Product candidates with strong competitive profiles Integrative approach through combination of therapeutics and diagnostics Transition

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation

More information

ArQule Jefferies Global Healthcare Conference June 2015

ArQule Jefferies Global Healthcare Conference June 2015 ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning

More information

INTERIM MANAGEMENT STATEMENT Q3 2017

INTERIM MANAGEMENT STATEMENT Q3 2017 INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:

More information

Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results

Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH

More information

ANNUAL REPORT 2017 PRESS & ANALYST CONFERENCE CALL MARTINSRIED, MARCH 22, 2018

ANNUAL REPORT 2017 PRESS & ANALYST CONFERENCE CALL MARTINSRIED, MARCH 22, 2018 ANNUAL REPORT 2017 PRESS & ANALYST CONFERENCE CALL MARTINSRIED, MARCH 22, 2018 Prof. Dolores J. Schendel, CEO/CSO Dr. Thomas Taapken, CFO Dr. Kai Pinkernell, SVP Clinical Affairs/CMO "Safe Harbor" Statement

More information

Living Immunotherapies. Corporate Presentation DECEMBER 2018

Living Immunotherapies. Corporate Presentation DECEMBER 2018 Living Immunotherapies Corporate Presentation DECEMBER 2018 All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation

More information

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell

More information

JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018

JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,

More information

Company update German Equity Forum, Frankfurt November 2010

Company update German Equity Forum, Frankfurt November 2010 Company update German Equity Forum, Frankfurt November 2010 At a glance Oncology-focused biopharmaceutical company Transition from R&D to commercially driven business Product candidates close to market

More information

Third Quarter 2018 Financial Results. November 1, 2018

Third Quarter 2018 Financial Results. November 1, 2018 Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key

More information

TOP-LINE DATA FROM THE RANDOMIZED PHASE 2 IMPULSE STUDY IN SMALL-CELL LUNG CANCER (SCLC): IMMUNOTHERAPEUTIC MAINTENANCE TREATMENT WITH LEFITOLIMOD

TOP-LINE DATA FROM THE RANDOMIZED PHASE 2 IMPULSE STUDY IN SMALL-CELL LUNG CANCER (SCLC): IMMUNOTHERAPEUTIC MAINTENANCE TREATMENT WITH LEFITOLIMOD Abstract #1527O TOP-LINE DATA FROM THE RANDOMIZED PHASE 2 IMPULSE STUDY IN SMALL-CELL LUNG CANCER (SCLC): IMMUNOTHERAPEUTIC MAINTENANCE TREATMENT WITH LEFITOLIMOD M. Thomas, S. Ponce-Aix, A. Navarro Mendivil,

More information

INTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY

INTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution

More information

Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007

Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007 Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements

More information

Corporate Presentation Asia Investment Series March 2018

Corporate Presentation Asia Investment Series March 2018 Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United

More information

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year

More information

Corporate Presentation September Nasdaq: ADXS

Corporate Presentation September Nasdaq: ADXS Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and

More information

Living Immunotherapies. Corporate Presentation OCTOBER 2018

Living Immunotherapies. Corporate Presentation OCTOBER 2018 Living Immunotherapies Corporate Presentation OCTOBER 2018 All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation

More information

Jefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer

Jefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this

More information

Oncology Therapeutics without Compromise APRIL 2011

Oncology Therapeutics without Compromise APRIL 2011 Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other

More information

3Q 2016 presentation

3Q 2016 presentation Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since

More information

Bank of America Merrill Lynch 2016 Health Care Conference

Bank of America Merrill Lynch 2016 Health Care Conference Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information

More information

Corporate Presentation

Corporate Presentation Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within

More information

PSMA-617 License Transaction. October 2, 2017

PSMA-617 License Transaction. October 2, 2017 PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,

More information

PRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March

PRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking

More information

PCI Biotech press release 24 th August Attachment

PCI Biotech press release 24 th August Attachment PCI Biotech press release 24 th August 2018 Attachment 1 BILE DUCT CANCER CLINICAL PHASE I STUDY Cohort IV is selected dose for pivotal study limited but promising data (per Aug 2018) Parameters 1) Average

More information

Investor Presentation

Investor Presentation Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance

More information

INTERIM RESULTS AS OF JUNE 30, 2017

INTERIM RESULTS AS OF JUNE 30, 2017 INTERIM RESULTS AS OF JUNE 30, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of

More information

Tivantinib Overview April 2016

Tivantinib Overview April 2016 Tivantinib Overview April 2016 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with

More information

Breathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018

Breathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018 Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation

More information

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business

More information

Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results

Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses

More information

Forward Looking Statements

Forward Looking Statements Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited

More information

CORPORATE PRESENTATION

CORPORATE PRESENTATION CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

Corcept Therapeutics, Inc.

Corcept Therapeutics, Inc. March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY

More information

INTERIM RESULTS AS OF MARCH 31, 2018

INTERIM RESULTS AS OF MARCH 31, 2018 INTERIM RESULTS AS OF MARCH 31, 2018 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of

More information

Bobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference

Bobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are

More information

Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC

Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts

More information

Pierre Legault CEO June 2, 2014

Pierre Legault CEO June 2, 2014 April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking

More information

THE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016

THE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016 THE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016 1 BAVARIAN NORDIC INVESTOR & ANALYST UPDATE & RECEPTION Welcome and Introduction to Bavarian Nordic s Cancer immunotherapy Programs Paul Chaplin,

More information

MDxHealth. Excellent Buy Opportunity. Research Note.

MDxHealth. Excellent Buy Opportunity. Research Note. Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February

More information

Company overview. Highlights for the 1 st quarter 2018 (January-March)

Company overview. Highlights for the 1 st quarter 2018 (January-March) Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of

More information

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

AVEO and Astellas Report Final Overall Survival Results from TIVO-1 AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,

More information

SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines

SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and

More information

MagForce AG Fighting Cancer with Nano Medicine

MagForce AG Fighting Cancer with Nano Medicine MagForce AG Fighting Cancer with Nano Medicine Bank of America Merrill Lynch 2013 Health Care Conference May 2013 Prof Hoda Tawfik COO, co-ceo MagForce AG Company Presentation Berlin, / Germany Martinsried,

More information

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,

More information

A world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP

A world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market

More information

PLEO-CMT Top-line Results. Presentation October 16, 2018

PLEO-CMT Top-line Results. Presentation October 16, 2018 PLEO-CMT Top-line Results Presentation October 16, 2018 Disclaimer References herein to this presentation (the Presentation ) shall mean and include this document, any oral presentation accompanying this

More information

Presentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011

Presentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011 Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business

More information

Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights

Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights November 10, 2014 7:00 AM ET Announces Submission of Letter of Intent to File MAA for Vosaroxin in Relapsed or

More information

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical

More information

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,

More information

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

Leading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products

Leading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products ALK at a glance The leading allergy immunotherapy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise SLIT- tablet portfolio

More information

Zacks Small-Cap Research

Zacks Small-Cap Research Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,

More information

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)

More information

Business Update & Financial Results for Q1 2018

Business Update & Financial Results for Q1 2018 Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma

More information

Jefferies 2014 Global Healthcare Conference. June 5, 2014

Jefferies 2014 Global Healthcare Conference. June 5, 2014 Jefferies 2014 Global Healthcare Conference June 5, 2014 ArQule, Inc. Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private

More information

Fight Cancer! Eine Initiative der Deutschen Biotechnologie

Fight Cancer! Eine Initiative der Deutschen Biotechnologie Fight Cancer! Eine Initiative der Deutschen Biotechnologie Diagnostik & Personalisierte Medizin: Guiding targeted therapies through diagnostics Professor Olaf G Wilhelm, MD, PhD CEO and co-founder of WILEX

More information

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major

More information

Revolutionizing the Treatment of Cancer

Revolutionizing the Treatment of Cancer Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may

More information

Pioneering vaccines that transform lives.

Pioneering vaccines that transform lives. Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy

More information

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major

More information

Cowen Annual Healthcare Conference. March 2018

Cowen Annual Healthcare Conference. March 2018 Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,

More information

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019 Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general

More information

Third Quarter 2015 Earnings Call. November 9, 2015

Third Quarter 2015 Earnings Call. November 9, 2015 Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

Photocure ASA Executing the Strategy

Photocure ASA Executing the Strategy Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address

More information

Small-Cap Research. Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report OUTLOOK

Small-Cap Research. Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report OUTLOOK Small-Cap Research May 25, 2017 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report DMPI: A New Phase

More information

Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results

Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016 Eiger

More information

Positioned for Growth

Positioned for Growth Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation

More information

Revolutionizing the Treatment of Cancer

Revolutionizing the Treatment of Cancer Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may

More information

Revolutionizing the Treatment of Cancer

Revolutionizing the Treatment of Cancer Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.

More information

For personal use only

For personal use only Prima BioMed Annual General Meeting CEO Presentation November 25, 2016 ASX:PRR; NASDAQ:PBMD Marc Voigt 1 Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

INTERIM RESULTS AS OF JUNE 30, 2016 CSE/OMX:BAVA, OTC:BVNRY

INTERIM RESULTS AS OF JUNE 30, 2016 CSE/OMX:BAVA, OTC:BVNRY INTERIM RESULTS AS OF JUNE 30, 2016 Q2 CSE/OMX:BAVA, OTC:BVNRY FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many

More information

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER

More information